Moneycontrol
HomeNewsOpinionCOVID-19 | How the State must deal with citizen’s personal data

COVID-19 | How the State must deal with citizen’s personal data

The same privacy concerns in the Kerala government’s Sprinklr deal exist with the Union government’s Aarogya Setu app too. Anonymising data or even obtaining ‘informed consent’ hardly addresses these

May 10, 2020 / 12:19 IST
Story continues below Advertisement

‘If you’re not paying for it…you are the product…’, goes the old saying.

A contract for analysis of data collected from quarantined persons, at ‘zero cost during COVID-19’, has landed the Kerala government in a novel controversy. Now, the Kerala High Court has put a spoke in the wheels, directing that the data be anonymised before it is handed over to the contractor (New York-based data analytics firm Sprinklr), as well as ‘informed consent’ be taken from citizens at the time of data collection. Other directions include a prohibition on Sprinklr sharing the data with any third party, or breaching confidentiality of the data in any way.

Story continues below Advertisement

The latter directions might well be sufficient to safeguard the privacy of the data sources (those from whom it is collected). However, the first two (anonymisation and ‘informed consent’), laudable as they are in intent, are merely a mirage from the point of privacy — and expose our lack of understanding of the true nature of data security. Again, these very same privacy concerns arise out of the Aarogya Setu app, aggressively promoted by the Union government.

Kerala signed an agreement with Sprinklr to analyse data (including personal details, co-morbidities, presence of elderly in their households, etc) collected by ASHA workers, apparently to assess the need and urgency for individual medical assistance. The State’s response to the high court sought to diminish concerns by claiming that the data was being stored in servers within India, and that the agreement contained confidentiality and privacy provisions.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show